Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study.
Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group. Piroth L, et al. Clin Infect Dis. 2015 Sep 1;61(5):817-25. doi: 10.1093/cid/civ381. Epub 2015 May 14. Clin Infect Dis. 2015. PMID: 25977266 Clinical Trial.
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team. Carrat F, et al. Among authors: piroth l. JAMA. 2004 Dec 15;292(23):2839-48. doi: 10.1001/jama.292.23.2839. JAMA. 2004. PMID: 15598915 Clinical Trial.
Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, Morand P, Lunel-Fabiani F, Salmon-Ceron D, Piroth L, Pialoux G, Bentata M, Cacoub P, Perronne C; ANRS Hc02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: piroth l. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):47-52. doi: 10.1097/01.qai.0000174649.51084.46. J Acquir Immune Defic Syndr. 2005. PMID: 16123681
Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.
Bani-Sadr F, Carrat F, Rosenthal E, Piroth L, Morand P, Lunel-Fabiani F, Bonarek M, Colin de Verdiere N, Pialoux G, Cacoub P, Pol S, Perronne C; ANRS HC02-Ribavic Study Team. Bani-Sadr F, et al. Among authors: piroth l. Clin Infect Dis. 2005 Dec 15;41(12):1806-9. doi: 10.1086/498312. Epub 2005 Nov 11. Clin Infect Dis. 2005. PMID: 16288408 Clinical Trial.
Hepatitis B virus-human immunodeficiency virus co-infection in France: a cross-sectional multicentre study.
Sène D, Pol S, Piroth L, Goujard C, Dellamonica P, Moussali J, Rey D, Loustaud-Ratti V, Alric L, Chousterman M, Borsa-Lebas F, Boucher O, Séréni D, Cacoub P; GERMIVIC Study Group. Sène D, et al. Among authors: piroth l. Epidemiol Infect. 2007 Apr;135(3):409-16. doi: 10.1017/S0950268806006947. Epub 2006 Jul 25. Epidemiol Infect. 2007. PMID: 16863601 Free PMC article.
393 results